Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Breast Cancer - Female
- Hormone Receptor Positive Malignant Neoplasm of Breast
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Only males
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03969121
- Collaborators
- Pfizer
- Investigators
- Principal Investigator: Masakazu Toi, MD,PhD Kyoto University, Professor of Breast Surgery Department Principal Investigator: Louis WC Chow, MD,PhD Organisation for Oncology and Translational Research (OOTR) Principal Investigator: Takayuki Ueno, MD,PhD Cancer Institute Hospital of JFCR, Department Director, Breast Surgical Oncology Department
Get Well Soon